<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436133</url>
  </required_header>
  <id_info>
    <org_study_id>GXIRB2020-0036</org_study_id>
    <nct_id>NCT04436133</nct_id>
  </id_info>
  <brief_title>Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)</brief_title>
  <official_title>A Randomized, Blind, and Positive Control Design to Evaluate the Immunization Efficacy of 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-26 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Vaccine and Serum Institute, China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu Institute of Biological Products Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simoon Record Pharma Information Consulting Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Kantorico Statistical Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Vaccine and Serum Institute, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 480 Chinese women aged 18-26 years old were enrolle，experimental group and the
      control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental
      group and 120 in the control group. All subjects enrolled in the upper arm deltoid muscle
      were injected with 3 doses of test vaccine or control vaccine according to the 0, 2, and 6
      months immunization program.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 22, 2020</start_date>
  <completion_date type="Anticipated">July 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HPV neutralizing antibodies GMT</measure>
    <time_frame>30 days after full immunization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV neutralizing antibody positive conversion rate（after full immunization 30 days）</measure>
    <time_frame>30 days after full immunization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Collect all SAEs</measure>
    <time_frame>through study completion, an average of 13 months</time_frame>
    <description>Vaccine-related and unrelated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collect AEs incidence</measure>
    <time_frame>Within 30 minutes of injection</time_frame>
    <description>Vaccine-related and unrelated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collect AEs incidence</measure>
    <time_frame>Within 30 days after inoculation</time_frame>
    <description>All AEs: incidence of AEs related to vaccines and unrelated
The rate of Solicited for AE
Non-collective AEs: incidence of AEs related to vaccines and unrelated
AE level 3 and above: incidence of vaccine-related and unrelated AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>collect AEs leading subject to withdrawal</measure>
    <time_frame>through study completion, an average of 13months</time_frame>
    <description>Incidence of vaccine-related and unrelated AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>collect All pregnancy conditions and pregnancy outcomes</measure>
    <time_frame>through study completion, an average of 13 months</time_frame>
    <description>collect pregnant woman Anti-HPV neutralizing antibody positive conversion rate and Anti-HPV neutralizing antibodies GMT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>HPV Infection</condition>
  <condition>HPV-Related Cervical Carcinoma</condition>
  <arm_group>
    <arm_group_label>vaccine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)</intervention_name>
    <description>Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle</description>
    <arm_group_label>vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9-valent HPV vaccine（Gardasil 9）</intervention_name>
    <description>Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle</description>
    <arm_group_label>Positive control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chinese women aged 18-26 who can provide legal identification;

          2. The subject has the ability to understand the research procedure and sign an informed
             consent;

          3. Subjects have the ability to read, understand, fill out diary cards/contact cards and
             other research application forms and promise to participate in regular follow-up as
             required by the research;

          4. No previous history of HPV vaccination, no participation in HPV vaccine clinical
             trials, and no plans to receive HPV vaccine during the study period; The subject was
             not breastfeeding or pregnant (negative urine pregnancy test), did not have a birth
             plan within 7 months of enrollment; and from day 1 of the last menstrual cycle to day
             0 of the study, did not have sex with men or with men Effective contraception was used
             during sex and no contraceptive failures occurred (examples of contraceptive failure
             include male condom rupture during sex). And agreed to continue to take effective
             contraceptive measures within the first 7 months after participating in the study
             (effective contraceptive measures include: oral contraceptives, hormone patches,
             intrauterine devices, condoms, cervical caps, etc.).

        First dose exclusion criteria:

          1. Previous history of cervical lesions (such as abnormal cervical cancer screening,
             history of CIN disease) or history of hysterectomy surgery (vaginal or total
             hysterectomy) or history of pelvic radiation therapy; previous history of external
             genital diseases (such as vulvar epithelium) Neoplasia, intraepithelial neoplasia and
             genital warts, etc.);

          2. Previous history of severe allergic reactions requiring medical intervention for any
             vaccine or drug (including yeast) (eg: anaphylactic shock, allergic throat edema,
             allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus
             reaction) Wait);

          3. Immune function is impaired or has been diagnosed with congenital or acquired
             immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia,
             systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile Rheumatoid
             arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;

          4. Long-term treatment with immunosuppressive agents, such as: long-term (more than 2
             weeks in a row) treatment with glucocorticoids (eg, prednisone or similar drugs);

          5. Receive any immunoglobulin or blood products within 3 months before vaccination, or
             plan to receive such products before the 7th month of the study;

          6. Received inactivated vaccine or recombinant vaccine within 14 days before vaccination,
             or received any live vaccine within 28 days;

          7. Loss of spleen or functional spleen, and removal of spleen or spleen caused by any
             situation;

          8. Has been diagnosed with a disease that may interfere with the progress or completion
             of the study, such as: suffering from severe cardiovascular disease (pulmonary heart
             disease, pulmonary edema), severe liver and kidney disease, diabetes with
             complications, etc.; or has been diagnosed with Infectious diseases, such as: active
             tuberculosis, hepatitis B, hepatitis C, etc.;

          9. A history of convulsions, epilepsy, encephalopathy, mental illness, family history of
             mental illness, etc.;

         10. There are thrombocytopenia or other coagulation disorders that can be
             contraindications to intramuscular injection; 11.3 days before the vaccination,
             suffering from acute disease or in the acute onset of chronic disease or using
             antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen,
             aspirin, loratadine, cetaxidine Tirizine, etc.);

        12.Body temperature before inoculation≥37.3℃(armpit body temperature); 13. People who have
        a systolic blood pressure ≥140mmHg and/or a diastolic blood pressure ≥90mmHg before
        enrollment; 14. Participate or plan to participate in other clinical trials (drugs,
        vaccines and medical devices) during the study; 15. Plan to move out of the local area
        before the end of the study or leave the area for a long time during the scheduled study
        visit;

        Exclusion criteria for second and third doses of vaccination:

          1. Before vaccination (the day of vaccination), pregnant or urine pregnancy test (HCG) is
             positive; Note: If the subject chooses to terminate the pregnancy, at least 6 weeks
             after the end of pregnancy and the urine pregnancy test is negative on the day before
             the vaccination, or the medical certificate of termination of pregnancy issued after
             the end of pregnancy indicates that HCG levels have returned to normal levels, you can
             continue Vaccination; if you choose to continue pregnancy, you will not be vaccinated
             for subsequent doses.

          2. Newly discovered or newly occurred conditions that meet the first dose exclusion
             criteria (except Articles 1 and 13);

          3. Other serious adverse events: The researcher decides whether to terminate the test
             vaccination according to his treatment needs;

          4. The investigator assessed any other reasons why the vaccination for the trial should
             be terminated.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mo Zhaojun, master</last_name>
    <phone>（+86）15177771508</phone>
    <email>mozhj@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liucheng Center for Disease Control and Prevention</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinhai Yang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

